2 May 2023
Agronomics Limited
("Agronomics" or the "Company")
Net Asset Value calculation as at 31 March 2023
Agronomics Limited (AIM:ANIC), the leading listed company focused on the field of cellular agriculture, announces that its unaudited Net Asset Valuation ("NAV") calculation as at closing on 31 March 2023 was 16.14 pence per share, broadly unchanged from 16.37 pence per share at 31 December 2022. Net Assets stand at £160 million, including investments of £131 million and uninvested cash of £29 million.
The share price of 10.90 pence at the 31 March 2023 close represents a discount of 32% to the NAV per share. The average discount to NAV per share over the last 12-month period was 4%. Under IFRS, the Company's unquoted investments are generally carried at cost or the most recent priced funding round.
Richard Reed, Chairman of Agronomics, commented: -
"Agronomics welcomed a new company to the portfolio this quarter, through its participation in the successfulUS$ 3.3 million Pre-seed financing of Wild Microbes, a company developing next-generation microbes for biomanufacturing.
This quarter also saw the second approval of a cultivated chicken product by the US Food and Drug Administration ("FDA"), with Good Meat receiving a 'No Questions letter'. The FDA is one of the most stringent regulatory bodies globally for food safety, and we still await the US Department of Agriculture to approve a cultivated meat product, allowing companies to begin commercialisation. We expect to see more regulatory approvals in the US for cultivated meat in the near term."
Corporate
On 23 February 2023, the Company announced the appointment of Marisa Drew to the Board of Directors. Marisa Drew is the inaugural Chief Sustainability Officer ("CSO") of Standard Chartered Bank Plc, responsible for setting the bank's sustainability strategy and the delivery of the firm's commitment to net zero carbon emissions by 2050 as well as overseeing the sustainable finance client-facing activities of the bank.
Financing
During the quarter ended 31 March 2023, the Company received notification of warrants being exercised. A total of 1,142 new ordinary shares were issued following the warrant exercise, for proceeds of £342.60. These funds, together with existing cash resources, will be utilised to provide finance for opportunities within the field of cellular agriculture, both by supporting existing companies, as well as identifying new opportunities in which to invest.
Investment review
On 25 January 2023, Liberation Labs Inc announced the acquisition of the land for its launch facility, which we believe will be the first dedicated, purpose-built, commercial, precision fermentation plant globally for food production.
On 7 February 2023, cultivated meat company CellX Limited announced the signing of a strategic partnership agreement with food manufacturing specialists Shanghai Tofflon Science and Technology Co., Ltd., aiming to accelerate the scale-up of cultivated meat in the Asian market with a new purpose-built facility.
On 23 February 2023, Agronomics participated in Wild Microbes US $3.3 million pre-Seed funding round, with a US$ 0.5 million investment. The investment was completed in the form of a Simple Agreement for Future Equity, and will provide Agronomics on conversion with an approximate equity ownership of 4.17% on a fully diluted basis. Wild Microbes' proprietary technology will allow it to genetically engineer novel microbial strains for use as host-organisms to produce proteins and other high value molecules.
Unaudited to 31 March 2023 £ |
||
Current Assets |
||
Investments |
130,895,484 |
|
Uninvested cash and deposits |
29,254,287 |
|
Trade and other receivables |
93,021 |
|
Current Liabilities |
||
Trade and other creditors |
(52,161) |
|
Net Assets |
160,190,631 |
|
Capital and Reserves |
||
Share capital |
992 |
|
Share premium |
134,209,188 |
|
Retained earnings |
25,980,451 |
|
Net assets |
160,190,631 |
|
Shares in Issue |
992,244,668 |
|
Net Asset Value per share |
16.14 pence |
The quoted investments within the portfolio are valued under IFRS at bid price.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014, as it forms part ofUKDomestic Law by virtue of theEuropean Union(Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
For further information please contact:
Agronomics Limited |
Beaumont Cornish Limited |
Canaccord Genuity Limited |
Cenkos Securities Plc |
Peterhouse Capital Limited |
TB Cardew |
The Company |
Nomad |
Joint Broker |
Joint Broker |
Joint Broker |
Public Relations |
Richard Reed Denham Eke |
Roland Cornish James Biddle |
Andrew Potts Harry Rees Alex Aylen (Head of Equities) |
Giles Balleny Michael Johnson |
Lucy Williams Charles Goodfellow |
Ed Orlebar Alistair Walker |
+44 (0) 1624 639396 |
+44 (0) 207 628 3396 |
+44 (0) 207 523 8000 |
+44 (0) 207 397 8900 |
+44 (0) 207 469 0936 |
+44 (0) 20 7930 0777 +44 (0) 7738 724 630 |
ENDS
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. ENDMSCBLLFBXELXBBQ
==